Vantus Wealth LLC Purchases New Holdings in Eli Lilly and Company $LLY

Vantus Wealth LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 797 shares of the company’s stock, valued at approximately $857,000.

A number of other large investors also recently bought and sold shares of the business. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the period. M.E. Allison & CO. Inc. lifted its position in Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after acquiring an additional 10 shares during the period. Tanager Wealth Management LLP lifted its position in Eli Lilly and Company by 2.6% during the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after acquiring an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC lifted its position in Eli Lilly and Company by 1.5% during the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC lifted its position in Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after acquiring an additional 10 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark now covers Eli Lilly’s full obesity drug portfolio, including the newly approved oral therapy Foundayo and injectable Zepbound. With all three major U.S. PBMs covering Lilly’s obesity medicines, the company gets broader insurance access and a stronger commercial outlook for its weight-loss franchise. PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook
• Positive Sentiment: Lilly announced a major Phase 3 win for Retevmo (selpercatinib), which cut the risk of recurrence or death by 83% in early-stage RET fusion-positive lung cancer. The data could expand the drug’s use and add to Lilly’s oncology growth pipeline. Unit of China’s Haisco, Eli Lilly sign collaboration, licensing deals
• Positive Sentiment: The company also announced new licensing and collaboration deals in Asia, including agreements with Hanmi and Haisco. Investors may view the deal-making as evidence that Lilly is actively building its next wave of products beyond obesity drugs. Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Today
• Neutral Sentiment: Several commentary pieces highlighted Lilly as one of the market’s top momentum stocks, and noted bullish analyst sentiment and strong Q1 revenue growth. These reports reinforce positive expectations, but they do not add materially new fundamentals. These 8 Words From Eli Lilly’s CEO Have Wall Street Turning Bullish
• Neutral Sentiment: One industry update noted Novo Nordisk’s oral GLP-1 pill is still outselling Lilly’s competing tablet, though growth is slowing. That suggests the obesity market remains highly competitive even as Lilly expands access. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
• Negative Sentiment: There was also a widely circulated note that Lilly shares had been trading down earlier in the period, but the article did not point to a new company-specific problem. Insider selling data in one report may also weigh on sentiment, though it is not necessarily a near-term fundamental issue. Eli Lilly and Company (NYSE:LLY) Trading Down 1.9% – What’s Next?

Analysts Set New Price Targets

A number of research analysts recently issued reports on LLY shares. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,079.96 on Tuesday. The company has a 50 day moving average price of $959.18 and a 200-day moving average price of $1,010.74. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The firm has a market capitalization of $1.02 trillion, a PE ratio of 38.36, a P/E/G ratio of 1.21 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the business posted $3.34 earnings per share. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.